|Bid||4.5000 x 800|
|Ask||4.5100 x 800|
|Day's Range||4.4700 - 4.5650|
|52 Week Range||2.3900 - 4.9600|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.14|
Subscribe to Yahoo Finance Plus to view Fair Value for VRAY
ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results.
Sarissa Capital is pushing to get a slate of directors on the board of pharmaceutical firm Amarin. Hudson Executive disclosed a large stake in radiation-treatment equipment maker ViewRay.
ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors (the "Board"), effective as of January 20, 2023.